10 noviembre 2011

Johnson & Johnson announces a clinical.A Study of Trabectedin or Dacarbazine for the Treatment of Patients with Advanced Liposarcoma or Leiomyosarcoma

P.D.: Se trata de las indicaciones por las que Yondelis ya esta Aprobado en 30 Paises Europeos y en 40 Paises del Area J&J ... un total de 70 Paises con la excepción de EEUU .


**********************


Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and PharmaMar are conducting a Phase 3 clinical trial for trabectedin or dacarbazine in patients with liposarcoma or leiomyosarcoma. This is a randomized (study drug assigned by chance), open-label (all patients and study staff know the identity of the assigned study drug), active-controlled (comparing to a different drug used for the same condition), parallel-group (different treatment groups continue with separate treatments throughout the study), multicenter study. This study will be divided into three phases, screening, treatment, and follow-up.

...